Bone Biologics Corp (BBLG) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Bone Biologics Corp (BBLG) has a cash flow conversion efficiency ratio of -0.098x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-591.38K) by net assets ($6.02 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Bone Biologics Corp - Cash Flow Conversion Efficiency Trend (2012–2024)
This chart illustrates how Bone Biologics Corp's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Bone Biologics Corp balance sheet liabilities for a breakdown of total debt and financial obligations.
Bone Biologics Corp Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Bone Biologics Corp ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Hansa Trust
LSE:HAN
|
0.007x |
|
Providence Gold Mines
V:PHD
|
0.002x |
|
Kestrel Gold Inc
V:KGC
|
-0.032x |
|
Himalaya Energi Perkasa Tbk PT
JK:HADE
|
-0.012x |
|
TTL Beteiligungs- und Grundbesitz-AG
F:TTO
|
0.226x |
|
Silver Castle Holdings Ltd
TA:SLCL
|
0.557x |
|
Lifeclean International AB
ST:LCLEAN
|
-1.773x |
|
ZW Data Action Technologies Inc
NASDAQ:CNET
|
-0.143x |
Annual Cash Flow Conversion Efficiency for Bone Biologics Corp (2012–2024)
The table below shows the annual cash flow conversion efficiency of Bone Biologics Corp from 2012 to 2024. For the full company profile with market capitalisation and key ratios, see BBLG market cap.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $3.48 Million | $-4.12 Million | -1.184x | +63.99% |
| 2023-12-31 | $2.91 Million | $-9.56 Million | -3.288x | -448.21% |
| 2022-12-31 | $5.95 Million | $-3.57 Million | -0.600x | -220.99% |
| 2021-12-31 | $6.58 Million | $-1.23 Million | -0.187x | -699.23% |
| 2020-12-31 | $-13.69 Million | $-426.93K | 0.031x | -88.62% |
| 2019-12-31 | $-11.87 Million | $-3.25 Million | 0.274x | -42.62% |
| 2018-12-31 | $-8.60 Million | $-4.10 Million | 0.477x | +20.37% |
| 2017-12-31 | $-8.40 Million | $-3.33 Million | 0.397x | -53.27% |
| 2016-12-31 | $-8.63 Million | $-7.33 Million | 0.849x | +35.98% |
| 2015-12-31 | $-5.68 Million | $-3.55 Million | 0.624x | -16.23% |
| 2014-12-31 | $-3.70 Million | $-2.76 Million | 0.745x | +68218.73% |
| 2013-12-31 | $-5.61 Million | $-6.12K | 0.001x | -98.86% |
| 2012-12-31 | $-4.68K | $-447.00 | 0.096x | -- |
About Bone Biologics Corp
Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's lead medical device NELL-1/DBM, an osteopromotive recombinant protein that provides target-specific control over bone regeneration. It also develops NELL-1/DBM fusion device used in lumbar spinal fusion. The company's NELL-1 platform technology use… Read more